Vascular Behçet syndrome: from pathogenesis to treatment
暂无分享,去创建一个
G. Hatemi | H. Direskeneli | D. Saadoun | G. Emmi | D. Prisco | E. Seyahi | A. Bettiol | F. Alibaz-Oner
[1] H. Direskeneli,et al. Pulmonary arterial wall thickness is increased in Behçet's disease patients with major organ ınvolvement: Is it a sign of severity? , 2022, Rheumatology.
[2] J. Karakaya,et al. A new tool supporting the diagnosis of childhood-onset Behçet's disease: venous wall thickness. , 2022, Rheumatology.
[3] A. Ishizu,et al. Presence of neutrophil extracellular traps in superficial venous thrombosis of Behçet’s disease , 2022, The Journal of dermatology.
[4] P. Demelo-Rodríguez,et al. Arterial and venous involvement in Behçet’s syndrome: a narrative review , 2022, Journal of Thrombosis and Thrombolysis.
[5] P. Cacoub,et al. Vascular Behçet's disease: a comparative study from Turkey and France. , 2021, Clinical and experimental rheumatology.
[6] W. Fu,et al. Long-term outcomes of endovascular treatment for aortic pseudoaneurysm in patients with Behçet’s disease , 2021, Vascular.
[7] A. Arcangeli,et al. A unique circulating miRNA profile highlights thrombo-inflammation in Behçet’s syndrome , 2021, Annals of the Rheumatic Diseases.
[8] Yin Su,et al. Efficacy and safety of tocilizumab in Behçet’s syndrome with refractory arterial lesions: a single-centre observational cohort study in China , 2021, Rheumatology.
[9] D. Attia. Behçet's disease phenotypes and clinical outcomes: A cohort study in egyptian patients. , 2021, Reumatologia clinica.
[10] H. Direskeneli,et al. Pathogenesis of Behçet's Syndrome: Genetic, Environmental and Immunological Factors , 2021, Frontiers in Medicine.
[11] A. Arcangeli,et al. Circulating miRNome profiling data in Behçet's syndrome , 2021, Data in brief.
[12] N. Taddei,et al. Neutrophil‐mediated mechanisms of damage and in‐vitro protective effect of colchicine in non‐vascular Behçet’s syndrome , 2021, Clinical and experimental immunology.
[13] H. Özer,et al. Diagnostic Performance of Lower Extremity Venous Wall Thickness and Laboratory Findings in the Diagnosis of the Behçet Disease , 2021, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.
[14] A. Ateş,et al. Analysis of vascular involvement in 460 patients with Behçet's syndrome: Clinical characteristics and associated factors. , 2021, Joint bone spine.
[15] A. Erden,et al. Budd–Chiari syndrome in Behçet’s disease: a retrospective multicenter study , 2021, Clinical Rheumatology.
[16] A. Soliman,et al. Vasculitis damage index in Behçet’s disease , 2021, Advances in Rheumatology.
[17] S. Ohno,et al. Treatment of Behçet's Disease: An Algorithmic Multidisciplinary Approach , 2021, Frontiers in Medicine.
[18] Y. Waheed,et al. Possible Role of Regulatory B Cells in Different Behçet’s Disease Phenotypes and Therapies: First Report from Egypt , 2021, Journal of inflammation research.
[19] A. Erden,et al. Predictors for the Risk and Severity of Post Thrombotic Syndrome in Vascular Behcet's Disease. , 2021, Journal of vascular surgery. Venous and lymphatic disorders.
[20] L. Biard,et al. Direct oral anticoagulant for venous thrombosis in Behçet's syndrome. , 2021, Autoimmunity reviews.
[21] A. Kasaeian,et al. Diagnosis of Behçet’s disease: clinical characteristics, diagnostic criteria, and differential diagnoses , 2021, BMC Rheumatology.
[22] V. Çobankara,et al. Ultrasonographic measurement of the vascular wall thickness and intima-media thickness in patients with Behçet’s disease with symptoms or signs of vascular involvement: A cross-sectional study , 2021, Archives of rheumatology.
[23] J. Guan,et al. Characteristics and phenotype heterogeneity in late-onset Behçet’s syndrome: a cohort from a referral center in China , 2020, Clinical Rheumatology.
[24] OUP accepted manuscript , 2021, Rheumatology.
[25] Xin Yu,et al. Neutrophil Extracellular Traps Promote Aberrant Macrophages Activation in Behçet’s Disease , 2021, Frontiers in Immunology.
[26] Jiali Chen,et al. Correspondence on ‘Critical role of neutrophil extracellular traps (NETs) in patients with Behcet’s disease’ , 2020, Annals of the Rheumatic Diseases.
[27] P. Tugwell,et al. Core Set of Domains for Outcome Measures in Behçet's Syndrome , 2020, Arthritis care & research.
[28] F. Sofi,et al. Butyrate Rich Diets Improve Redox Status and Fibrin Lysis in Behçet's Syndrome. , 2020, Circulation research.
[29] D. Isenberg,et al. Thrombotic antiphospholipid syndrome: A practical guide to diagnosis and management , 2020, Thrombosis Research.
[30] H. Direskeneli,et al. Femoral Vein Wall Thickness Measurement May Be a Distinctive Diagnostic Tool to Differentiate Behçet’s Disease with Intestinal Involvement and Crohn’s Disease , 2020, Digestive Diseases and Sciences.
[31] T. Ergun,et al. Femoral vein wall thickness measurement: A new diagnostic tool for Behçet's disease. , 2020, Rheumatology.
[32] D. Attia. Behçet's Disease Phenotypes and Clinical Outcomes: A Cohort Study in Egyptian Patients. , 2020, Reumatologia clinica.
[33] C. Lee,et al. Surgical experience of Behcet's disease involving the peripheral artery. , 2020, Annals of vascular surgery.
[34] Fengchun Zhang,et al. A pilot study of tofacitinib for refractory Behçet’s syndrome , 2020, Annals of the Rheumatic Diseases.
[35] G. Emmi,et al. Behçet: the syndrome. , 2020, Rheumatology.
[36] P. Demelo-Rodríguez,et al. Chronic Budd–Chiari syndrome in Behçet's disease successfully managed with transjugular intrahepatic portosystemic shunt: a case report and literature review , 2020, Clinical Journal of Gastroenterology.
[37] T. Ergun,et al. Efficacy of TNFα inhibitors for refractory vascular Behçet's disease: A multicenter observational study of 27 patients and a review of the literature , 2020, International journal of rheumatic diseases.
[38] Md. Asiful Islam,et al. Prevalence of antiphospholipid antibodies in Behçet's disease: A systematic review and meta-analysis , 2020, PloS one.
[39] S. Turroni,et al. Modulation of gut microbiota through nutritional interventions in Behçet’s syndrome patients (the MAMBA study): study protocol for a randomized controlled trial , 2019, Trials.
[40] L. Chiche,et al. Factors influencing the recurrence of arterial involvement after surgical repair in Behçet disease. , 2019, Journal of Vascular Surgery.
[41] G. Hatemi,et al. Clinical course of acute deep vein thrombosis of the legs in Behçet's syndrome. , 2020, Rheumatology.
[42] Yining Wang,et al. The Clinical Features, Risk Factors, and Outcome of Aneurysmal Lesions in Behcet's Disease , 2019, Journal of immunology research.
[43] N. Taddei,et al. Stem-Cell-Derived Circulating Progenitors Dysfunction in Behçet's Syndrome Patients Correlates With Oxidative Stress , 2019, Front. Immunol..
[44] G. Hatemi,et al. Treating the Different Phenotypes of Behçet's Syndrome , 2019, Front. Immunol..
[45] M. Kizilay,et al. Coronary Involvement in Behçet's Disease: what are its Risks and Prognosis? (Rare Cases and Literature Review) , 2019, Brazilian journal of cardiovascular surgery.
[46] H. Ebada,et al. Characteristics and outcome of primary Budd-Chiari syndrome due to Behçet's syndrome. , 2019, Clinics and research in hepatology and gastroenterology.
[47] H. Yazici,et al. Increased frequency of obstructive sleep apnea syndrome in Behçet's syndrome patients with superior vena cava syndrome. , 2019, Clinical and experimental rheumatology.
[48] E. S. Durmaz,et al. Increased vein wall thickness in Behçet disease. , 2019, Journal of vascular surgery. Venous and lymphatic disorders.
[49] Xiao-juan Guo,et al. Multiple cardiovascular involvements in Behçet’s disease: unique utility of 18F-FDG PET/CT in diagnosis and follow-up , 2019, European Journal of Nuclear Medicine and Molecular Imaging.
[50] A. Cazes,et al. Critical role of neutrophil extracellular traps (NETs) in patients with Behcet’s disease , 2019, Annals of the rheumatic diseases.
[51] G. Hatemi,et al. Behçet's Syndrome as a Model of Thrombo-Inflammation: The Role of Neutrophils , 2019, Front. Immunol..
[52] J. Guan,et al. Demography of vascular Behcet’s disease with different gender and age: an investigation with 166 Chinese patients , 2019, Orphanet Journal of Rare Diseases.
[53] N. Taddei,et al. Behçet’s syndrome as a tool to dissect the mechanisms of thrombo‐inflammation: clinical and pathogenetic aspects , 2018, Clinical and experimental immunology.
[54] T. Ergun,et al. Venous vessel wall thickness in lower extremity is increased in male patients with Behcet’s disease , 2019, Clinical Rheumatology.
[55] E. Seyahi. Phenotypes in Behçet’s syndrome , 2019, Internal and Emergency Medicine.
[56] H. Yazici,et al. Assessment of deep venous thrombosis in the lower extremity in Behçet’s syndrome: MR venography versus Doppler ultrasonography , 2019, Internal and Emergency Medicine.
[57] E. Silvestri,et al. Behçet's disease as a cause of cerebral sinus vein thrombosis: an emerging role. , 2018, Rheumatology.
[58] B. Zeydan,et al. Behçet’s disease as a causative factor of cerebral venous sinus thrombosis: subgroup analysis of data from the VENOST study , 2018, Rheumatology.
[59] J. Mao,et al. Local infiltration with cocktail analgesics during 2 level lumbar spinal fusion surgery , 2019, Medicine.
[60] L. Biard,et al. Efficacy of anti-TNF alpha in severe and refractory major vessel involvement of Behcet's disease: A multicenter observational study of 18 patients. , 2018, Clinical immunology.
[61] E. Silvestri,et al. Vascular Behçet’s syndrome: an update , 2018, Internal and Emergency Medicine.
[62] D. Nassar,et al. Neutrophils contribute to vasculitis by increased release of neutrophil extracellular traps in Behçet's disease. , 2018, Journal of dermatological science.
[63] V. Hamuryudan,et al. Surgical Treatment of Pulmonary Complications in Behçet's Syndrome. , 2018, Seminars in thoracic and cardiovascular surgery.
[64] R. Moots,et al. Management of major organ involvement of Behçet’s syndrome: a systematic review for update of the EULAR recommendations , 2018, Rheumatology.
[65] P. Libby,et al. Neutrophil Extracellular Traps Induce Endothelial Cell Activation and Tissue Factor Production Through Interleukin-1&agr; and Cathepsin G , 2018, Arteriosclerosis, thrombosis, and vascular biology.
[66] A. Vaglio,et al. Adalimumab‐Based Treatment Versus Disease‐Modifying Antirheumatic Drugs for Venous Thrombosis in Behçet's Syndrome , 2018, Arthritis & rheumatology.
[67] C. Bal,et al. Why are male patients with Behçet's disease prone to thrombosis? A rotational thromboelastographic analysis. , 2018, Clinical and experimental rheumatology.
[68] A. Vaglio,et al. Hemoptysis in Behçet’s syndrome: from bedside to bench? , 2018, Internal and Emergency Medicine.
[69] Iman M Eissa,et al. Vision-Threatening Behcet's Disease: Severity of Ocular Involvement Predictors , 2018, Journal of ophthalmology.
[70] R. Moots,et al. 2018 update of the EULAR recommendations for the management of Behçet’s syndrome , 2018, Annals of the rheumatic diseases.
[71] S. Hazen,et al. Microbial modulation of cardiovascular disease , 2018, Nature Reviews Microbiology.
[72] G. Hatemi,et al. Behçet syndrome: a contemporary view , 2018, Nature Reviews Rheumatology.
[73] M. Delgado-Rodríguez,et al. Systematic review and meta-analysis. , 2017, Medicina intensiva.
[74] Dennis Andersson,et al. A retrospective cohort study , 2018 .
[75] F. Davatchi,et al. Imaging manifestations of Behcet's disease: Key considerations and major features. , 2018, European journal of radiology.
[76] H. Direskeneli,et al. Outcomes of Patients with Behçet's Syndrome after Pulmonary Endarterectomy , 2017, The Thoracic and Cardiovascular Surgeon.
[77] B. Goksel,et al. A Multicenter Study of 1144 Patients with Cerebral Venous Thrombosis: The VENOST Study. , 2017, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.
[78] M. Fafutis-Morris,et al. Neutrophil Extracellular Traps and Its Implications in Inflammation: An Overview , 2017, Front. Immunol..
[79] F. Shahram,et al. Behcet’s disease: epidemiology, clinical manifestations, and diagnosis , 2017, Expert review of clinical immunology.
[80] Wenjie Zheng,et al. Cerebral venous sinus thrombosis in Behçet’s disease: a retrospective case-control study , 2017, Clinical Rheumatology.
[81] M. Laffan,et al. A low balance between microparticles expressing tissue factor pathway inhibitor and tissue factor is associated with thrombosis in Behçet’s Syndrome , 2016, Scientific Reports.
[82] H. Yazici,et al. Behçet syndrome: the vascular cluster. , 2016, Turkish journal of medical sciences.
[83] B. Knebelmann,et al. Case report and literature review , 2016, Medicine.
[84] F. Numan,et al. Bronchial artery enlargement may be the cause of recurrent haemoptysis in Behçet's syndrome patients with pulmonary artery involvement during follow-up. , 2016, Clinical and experimental rheumatology.
[85] T. Ergun,et al. Post-thrombotic syndrome and venous disease-specific quality of life in patients with vascular Behçet's disease. , 2016, Journal of vascular surgery. Venous and lymphatic disorders.
[86] E. Seyahi. Behçet's disease: How to diagnose and treat vascular involvement. , 2016, Best practice & research. Clinical rheumatology.
[87] S. Sangle,et al. Pulmonary artery aneurysms in Behçet's disease treated with anti-TNFα: A case series and review of the literature. , 2016, Autoimmunity reviews.
[88] S. Nishio,et al. The responses of macrophages in interaction with neutrophils that undergo NETosis. , 2016, Journal of autoimmunity.
[89] Rosanna Abbate,et al. Neutrophil Activation Promotes Fibrinogen Oxidation and Thrombus Formation in Behçet Disease , 2016, Circulation.
[90] H. Direskeneli,et al. Dual effects of testosterone in Behcet's disease: implications for a role in disease pathogenesis , 2013, Genes and Immunity.
[91] A. Stavropoulos,et al. Retrospective case control study , 2016 .
[92] G. Hatemi,et al. Pulmonary artery involvement in Behçet׳s syndrome: Effects of anti-Tnf treatment. , 2015, Seminars in arthritis and rheumatism.
[93] F. Nevens,et al. Budd-Chiari syndrome , 2015, United European gastroenterology journal.
[94] P. Merkel,et al. Current Status, Goals, and Research Agenda for Outcome Measures Development in Behçet Syndrome: Report from OMERACT 2014 , 2015, The Journal of Rheumatology.
[95] V. Oktay,et al. Venous claudication in Behçet's disease. , 2015, Journal of vascular surgery.
[96] V. Jiménez‐Yuste,et al. Endothelial Dysfunction and Altered Coagulation As Mediators of Thromboembolism in Behçet Disease , 2015, Seminars in Thrombosis & Hemostasis.
[97] N. Sut,et al. Pulmonary artery aneurysms in Behçet's syndrome: a review of the literature with emphasis on geographical differences. , 2015, Clinical and experimental rheumatology.
[98] H. Nasr,et al. Superficial thrombophlebitis (superficial venous thrombosis) , 2015, BMJ : British Medical Journal.
[99] A. Amedei,et al. Microparticles: Bridging the Gap between Autoimmunity and Thrombosis , 2015, Seminars in Thrombosis & Hemostasis.
[100] W. Krautgartner,et al. The Role of Reactive Oxygen Species (ROS) in the Formation of Extracellular Traps (ETs) in Humans , 2015, Biomolecules.
[101] Matteo Becatti,et al. Thrombosis in vasculitis: from pathogenesis to treatment , 2015, Thrombosis Journal.
[102] S. Rampelli,et al. Behçet's syndrome patients exhibit specific microbiome signature. , 2015, Autoimmunity reviews.
[103] E. Çağlar,et al. An outcome survey of 43 patients with Budd-Chiari syndrome due to Behçet's syndrome followed up at a single, dedicated center. , 2015, Seminars in arthritis and rheumatism.
[104] K. Dia,et al. Superior vena cava syndrome revealing a Behçet’s disease , 2015, Thrombosis Journal.
[105] F. Bonneville. Imaging of cerebral venous thrombosis. , 2014, Diagnostic and interventional imaging.
[106] N. Sut,et al. Vascular involvement in Behçet's syndrome: a retrospective analysis of associations and the time course. , 2014, Rheumatology.
[107] U. Kalyoncu,et al. A rare but serious manifestation of Behçet's disease: intracardiac thrombus in 22 patients. , 2014, Clinical and experimental rheumatology.
[108] D. Firmin,et al. Magnetic resonance imaging of vein wall thickness in patients with Behçet's syndrome. , 2014, Clinical and experimental rheumatology.
[109] G. Espinosa,et al. Endogenous thrombin potential in Behçet's disease: relationship with thrombosis and anticoagulant therapy. , 2014, Clinical and experimental rheumatology.
[110] A. Hamzaoui,et al. Vena cava thrombosis in Behçet's disease. , 2014, Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology.
[111] A. Pathare,et al. Haemostatic Parameters in Patients with Behçet's Disease. , 2014, Sultan Qaboos University medical journal.
[112] J. Piette,et al. Ethnicity and association with disease manifestations and mortality in Behçet’s disease , 2014, Orphanet Journal of Rare Diseases.
[113] D. Valla,et al. Behcet’s disease in budd-chiari syndrome , 2013, Orphanet Journal of Rare Diseases.
[114] T. Ergun,et al. Evaluation of asymptomatic venous disease by venous Doppler ultrasonography in patients with Behcet's disease without overt thrombosis , 2014, Clinical Rheumatology.
[115] T. Chinet,et al. 18F-fluorodeoxyglucose-positron emission tomography scanning is a useful tool for therapy evaluation of arterial aneurysm in Behçet's disease. , 2013, Joint, bone, spine : revue du rhumatisme.
[116] H. Yazici,et al. Fever in Behçet's syndrome. , 2013, Clinical and experimental rheumatology.
[117] Xuemei Li,et al. Major vascular involvement in Behçet’s disease: a retrospective study of 796 patients , 2013, Clinical Rheumatology.
[118] K. Park,et al. Peripheral arterial involvement in Behcet’s disease: an analysis of the results from a Korean referral center , 2013, Rheumatology International.
[119] P. Marik,et al. Narrative Review , 2012, Journal of intensive care medicine.
[120] J. Piette,et al. Immunosuppressants reduce venous thrombosis relapse in Behçet's disease. , 2012, Arthritis and rheumatism.
[121] H. Yazıcı,et al. Behçet Syndrome: Is It One Condition? , 2012, Clinical Reviews in Allergy & Immunology.
[122] N. Sut,et al. The papulopustular lesion/arthritis cluster of Behçet's syndrome also clusters in families. , 2012, Rheumatology.
[123] Oliver Soehnlein,et al. Multiple roles for neutrophils in atherosclerosis. , 2012, Circulation research.
[124] E. Mohammadi,et al. Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.
[125] R. Gershoni-baruch,et al. Vascular behcet and mutations in thrombogenic genes: methylene tetrahydrofolate reductase, factor V, and prothrombin. , 2012, Genetic testing and molecular biomarkers.
[126] G. Hatemi,et al. Pulmonary Artery Involvement and Associated Lung Disease in Behçet Disease: A Series of 47 Patients , 2012, Medicine.
[127] P. Cluzel,et al. Long-Term Outcome of Arterial Lesions in Behçet Disease: A Series of 101 Patients , 2012, Medicine.
[128] J. Piette,et al. Spectrum of Cardiac Lesions in Behçet Disease: A Series of 52 Patients and Review of the Literature , 2012, Medicine.
[129] H. Yazici,et al. Management and prognosis of nonpulmonary large arterial disease in patients with Behçet disease. , 2012, Journal of vascular surgery.
[130] S. Saip,et al. Clinical characteristics of pediatric-onset neuro-Behçet disease , 2011, Neurology.
[131] H. Yazici,et al. The estimated pulmonary artery pressure can be elevated in Behçet's syndrome. , 2011, Respiratory medicine.
[132] M. Macey,et al. Age, gender and disease-related platelet and neutrophil activation ex vivo in whole blood samples from patients with Behçet's disease. , 2011, Rheumatology.
[133] A. Gyedu,et al. Surgical treatment of peripheral aneurysms in patients with Behcet's disease. , 2011, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.
[134] E. Onur,et al. Oxidative stress impairs endothelial nitric oxide levels in Behçets’ disease , 2011, Cutaneous and ocular toxicology.
[135] Y. Ishigatsubo,et al. Characteristics of vascular involvement in Behçet's disease in Japan: a retrospective cohort study. , 2011, Clinical and experimental rheumatology.
[136] Umair Khalid,et al. Hughes-Stovin Syndrome , 2011, Orphanet journal of rare diseases.
[137] Sung Bin Cho,et al. Detection of cardiovascular system involvement in Behçet's disease using fluorodeoxyglucose positron emission tomography. , 2011, Seminars in arthritis and rheumatism.
[138] S. Sungkanuparph,et al. A CASE SERIES AND REVIEW OF THE LITERATURE , 2011 .
[139] H. Erdem,et al. Investigation of the veins in patients with Behçet’s disease with no known vascular event by Doppler ultrasonography , 2012, Rheumatology International.
[140] A. Pathare,et al. Pattern and outcome of vascular involvement of Omani patients with Behcet’s disease , 2011, Rheumatology International.
[141] J. Ferro,et al. Cerebral venous thrombosis in Behçet’s disease: a systematic review , 2011, Journal of Neurology.
[142] F. Dentali,et al. Homocysteine in Vascular Behçet Disease: A Meta-Analysis , 2010, Arteriosclerosis, thrombosis, and vascular biology.
[143] Z. Amoura,et al. Mortality in Behçet's disease. , 2010, Arthritis and rheumatism.
[144] W. Ruf,et al. Neutrophils release brakes of coagulation , 2010, Nature Medicine.
[145] G. Poli,et al. A study on thrombophilic factors in Italian Behcet's patients. , 2010, Joint, bone, spine : revue du rhumatisme.
[146] F. Shahram,et al. Comparison of existing disease activity indices in the follow-up of patients with Behçet’s disease , 2009, Modern rheumatology.
[147] P. Prandoni,et al. Definition of post‐thrombotic syndrome of the leg for use in clinical investigations: a recommendation for standardization , 2009, Journal of thrombosis and haemostasis : JTH.
[148] D. Dormont,et al. Cerebral venous thrombosis in Behçet's disease. , 2009, Arthritis and rheumatism.
[149] N. Yesilot,et al. Cerebral venous thrombosis in Behçet’s disease compared to those associated with other etiologies , 2009, Journal of Neurology.
[150] A. Mert,et al. Significance of serum interleukin‐8 levels in patients with Behcet's disease: high levels may indicate vascular involvement , 2009, International journal of dermatology.
[151] R. Yeung,et al. Matrix metalloproteinase 9 activity leads to elastin breakdown in an animal model of Kawasaki disease. , 2008, Arthritis and rheumatism.
[152] Jae-Kwan Song,et al. Cardiac Behçet Disease Presenting as Aortic Valvulitis/Aortitis or Right Heart Inflammatory Mass: A Clinicopathologic Study of 12 Cases , 2008, The American journal of surgical pathology.
[153] H. Yazici,et al. The Unique Features of Vasculitis in Behçet’s Syndrome , 2008, Clinical reviews in allergy & immunology.
[154] F. Schmidt. Meta-Analysis , 2008 .
[155] Pedagógia,et al. Cross Sectional Study , 2019 .
[156] A. Vayá,et al. Platelet Activation and Red Blood Cell Phosphatidylserine Exposure Evaluated by Flow Cytometry in Patients with Behçet’s Disease: Are They Related to Thrombotic Events? , 2008, Pathophysiology of Haemostasis and Thrombosis.
[157] E. Koh,et al. Treatment of venous thrombosis associated with Behcet’s disease: immunosuppressive therapy alone versus immunosuppressive therapy plus anticoagulation , 2008, Clinical Rheumatology.
[158] S. Yurdakul,et al. A cost analysis of Behcet's syndrome in Turkey. , 2006, Rheumatology.
[159] P. Mahadevan,et al. An overview , 2007, Journal of Biosciences.
[160] H. Kwon,et al. Surgical outcomes and risk factors for postoperative complications in patients with Behcet’s disease , 2007, Clinical Rheumatology.
[161] S. Akar,et al. Circulated Activated Platelets and Increased Platelet Reactivity in Patients With Behçet’s Disease , 2006, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.
[162] M. Nazıroğlu,et al. Asymmetric dimethylarginine and nitric oxide levels as signs of endothelial dysfunction in Behcet's disease. , 2006, Annals of clinical and laboratory science.
[163] F. España,et al. Dyslipidaemia in Behçet’s disease as a thrombotic risk factor , 2006, Annals of the rheumatic diseases.
[164] D. Corella,et al. Thrombophilic risk factors and homocysteine levels in Behçet’s disease in eastern Spain and their association with thrombotic events , 2006, Thrombosis and Haemostasis.
[165] S. Esmat,et al. Lipoprotein (a) and nitrites in Behcet's disease: relationship with disease activity and vascular complications. , 2006, European journal of dermatology : EJD.
[166] M. Can,et al. Lipid peroxidation and homocysteine levels in Behçet's disease , 2006, Clinical chemistry and laboratory medicine.
[167] N. Yenice,et al. Nitric oxide, lipid peroxidation and antioxidant defence system in patients with active or inactive Behçet's disease , 2005, The British journal of dermatology.
[168] Y. Turkoz,et al. Serum Levels of Soluble P-Selectin Are Increased and Associated With Disease Activity in Patients With Behçet's Syndrome , 2005, Mediators of inflammation.
[169] O. Uzun,et al. Pulmonary vasculitis in behcet disease: a cumulative analysis. , 2005, Chest.
[170] C. Beyan,et al. Von Willebrand factor antigen levels in Behçet disease , 2005, American journal of hematology.
[171] A. Kızıltunç,et al. Levels of soluble E-selectin in patients with active Behçet’s disease , 2005, Clinical Rheumatology.
[172] F. Numan,et al. Pulmonary artery aneurysms in Behçet syndrome. , 2004, The American journal of medicine.
[173] H. Yazıcı,et al. Cerebral venous thrombosis is associated with major vessel disease in Behçet’s syndrome , 2004, Annals of the rheumatic diseases.
[174] M. Ehrenfeld,et al. Thrombophilic factors are not the leading cause of thrombosis in Behçet’s disease , 2004, Annals of the rheumatic diseases.
[175] F. España,et al. Activated protein C levels in Behçet's disease and risk of venous thrombosis , 2004, British journal of haematology.
[176] A. Silman,et al. Development of the BD-QoL: a quality of life measure specific to Behçet's disease. , 2004, The Journal of rheumatology.
[177] H. Karabulut,et al. Factor V Leiden and prothrombin gene G20210A mutations in ocular Behçet disease. , 2003, Acta ophthalmologica Scandinavica.
[178] K. Dilek,et al. Arterial lesions in Behçet's disease. , 2003, VASA. Zeitschrift fur Gefasskrankheiten.
[179] K. Tanriverdi,et al. Methylenetetrahydrofolate reductase gene C677T mutation and plasma homocysteine level in Behçet's disease , 2003, Rheumatology International.
[180] N. Seyahi,et al. The Long-Term Mortality and Morbidity of Behçet Syndrome: A 2-Decade Outcome Survey of 387 Patients Followed at a Dedicated Center , 2003, Medicine.
[181] A. Tennant,et al. The Behçet's disease activity index. , 2003, Advances in experimental medicine and biology.
[182] O. Kim,et al. Homozygous C677T mutation in the MTHFR gene as an independent risk factor for multiple small-artery occlusions. , 2003, Thrombosis research.
[183] Jong Wan Kim,et al. The clinical features of Behcet's disease in Yongdong districts: analysis of a cohort followed from 1997 to 2001. , 2002, Journal of Korean medical science.
[184] I. Fresko,et al. Target organ associations in Turkish patients with Behçet's disease: a cross sectional study by exploratory factor analysis. , 2002, The Journal of rheumatology.
[185] R. A. Najim,et al. Dapsone in Behçet's Disease: A Double‐Blind, Placebo‐Controlled, Cross‐Over Study , 2002, The Journal of dermatology.
[186] A. Orem,et al. The evaluation of autoantibodies against oxidatively modified low-density lipoprotein (LDL), susceptibility of LDL to oxidation, serum lipids and lipid hydroperoxide levels, total antioxidant status, antioxidant enzyme activities, and endothelial dysfunction in patients with Behçet's disease. , 2002, Clinical biochemistry.
[187] Sang-Woon Choi,et al. Coagulation parameters and plasma total homocysteine levels in Behcet's disease. , 2002, Thrombosis Research.
[188] G. Espinosa,et al. Vascular involvement in Behçet's disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin. , 2002, The American journal of medicine.
[189] G. Polat,et al. Association of the platelet glycoprotein Ia C807T/G873A gene polymorphism and thrombosis in Behçet patients. , 2002, Haematologia.
[190] M. Akarsu,et al. Increased levels of tissue factor pathway inhibitor may reflect disease activity and play a role in thrombotic tendency in Behçet's disease , 2001, American journal of hematology.
[191] T. Ergun,et al. Neutrophil activation in Behçet's disease. , 2001, Clinical and experimental rheumatology.
[192] E. Tasali,et al. Pulmonary manifestations of Behçet's disease , 2001, Thorax.
[193] A. Denman,et al. Thrombosis in Behçet's disease: a retrospective survey from a single UK centre. , 2001, Rheumatology.
[194] S. Yurdakul,et al. Anticardiolipin antibodies in Behçet's disease: a reassessment. , 2001, Rheumatology.
[195] G. Kural,et al. Lipoprotein (a) in Behçet's Disease as an Indicator of Disease Activity and in Thrombotic Complications , 2001, European journal of ophthalmology.
[196] E. Tasali,et al. Pulmonary manifestations of Behçet's disease. , 2001, Thorax.
[197] A. Elhan,et al. Effects of factor V gene G1691A, methylenetetrahydrofolate reductase gene C677T, and prothombin gene G20210A mutations on deep venous thrombogenesis in Behçet's disease. , 2000, The Journal of rheumatology.
[198] L. Tokgözoğlu,et al. Hyperhomocysteinaemia and activated protein C resistance in Behçet’s disease , 2000, Journal of internal medicine.
[199] N. Mogulkoc,et al. Intracardiac thrombus in Behçet's disease: a systematic review. , 2000, Chest.
[200] A. Siegbahn,et al. Haemostasis in patients with Behçet's disease. , 2000, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.
[201] Nishikimi,et al. Neutrophil and endothelial cell activation in the vasa vasorum in vasculo‐Behçet disease , 2000, Histopathology.
[202] T. Tekinay,et al. Procoagulant mutations and venous thrombosis in Behçet's disease. , 1999, Rheumatology.
[203] I. Lavi,et al. Thrombophilic factors and their relation to thromboembolic and other clinical manifestations in Behçet's disease. , 1999, The Journal of rheumatology.
[204] R. Vaughan,et al. Factor V Leiden mutation is associated with ocular involvement in Behçet disease. , 1999, American journal of ophthalmology.
[205] O. Değer,et al. Autoantibodies against Oxidatively Modified Low-Density Lipoprotein in Patients with Behçet’s Disease , 1999, Dermatology.
[206] A. Ferrante,et al. Enhancement of endothelial cell E-selectin expression by sera from patients with active Behçet's disease: moderate correlation with anti-endothelial cell antibodies and serum myeloperoxidase levels. , 1999, Clinical immunology.
[207] M. Nalçacı,et al. Antithrombin III, Protein C and Protein S Plasma Levels in Patients with Behçet's Disease , 1998, The Journal of international medical research.
[208] N. Allı,et al. Protein C and protein S activities in Behçet's disease as risk factors of thrombosis. , 1998, International journal of dermatology.
[209] Ş. Kirazlı,et al. Activated protein C resistance in Behçet's disease , 1998, Rheumatology International.
[210] O. Değer,et al. Relationship between lipid peroxidation and disease activity in patients with Behçet's disease. , 1997, Journal of dermatological science.
[211] K. Dellagi,et al. Protein S deficiency and antibodies to protein S in patients with Behçet's disease. , 1997, Thrombosis research.
[212] S. Yurdakul,et al. Management of aneurysms in Behçet's syndrome: an analysis of 24 patients. , 1997, Surgery.
[213] M. Inanç,et al. Coagulation factor V gene mutation increases the risk of venous thrombosis in behçet's disease. , 1996, British journal of rheumatology.
[214] Ş. Kirazlı,et al. Impaired haemostatic kinetics and endothelial function in Behçet's disease , 1996, Journal of internal medicine.
[215] O. Ozcebe,et al. Haemostatic markers of procoagulant imbalance in Behçet's disease , 1996, European journal of haematology.
[216] A. Gürler,et al. Evaluation of peripheral vascular system disorders in vascular symptom--free Behçet's disease. , 1996, Cardiovascular surgery.
[217] H. Direskeneli,et al. Neutrophil adhesion to endothelial cells and factors affecting adhesion in patients with Behçet's disease. , 1996, Annals of the rheumatic diseases.
[218] B. Wechsler,et al. Arterial lesions in Behçet's disease. A study in 25 patients. , 1995, The Journal of rheumatology.
[219] A. Gürler,et al. Plasma von Willebrand factor, tissue plasminogen activator, plasminogen activator inhibitor, and antithrombin III levels in Behçet's disease. , 1995, Scandinavian journal of rheumatology.
[220] Y. Berkmen,et al. Thoracic involvement in Behçet's disease: pathologic, clinical, and imaging features. , 1995, AJR. American journal of roentgenology.
[221] G. Dudbridge. A contemporary view , 1995 .
[222] A. Bradbury,et al. Surgical aspects of Behçet's disease , 1994, The British journal of surgery.
[223] F. Numan,et al. Pulmonary arterial aneurysms in Behçet's syndrome: a report of 24 cases. , 1994, British journal of rheumatology.
[224] D. Menon,et al. Coagulation and Fibrinolytic Activity in Behçet's Disease , 1991, Thrombosis and Haemostasis.
[225] J. Sadler,et al. Regulation of thrombomodulin by tumor necrosis factor-alpha: comparison of transcriptional and posttranscriptional mechanisms. , 1991, Blood.
[226] R. Powell,et al. Defective fibrinolysis in Behçet's syndrome: significance and possible mechanisms. , 1989, Annals of the rheumatic diseases.
[227] R. Rosenberg,et al. Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells , 1988, Molecular and cellular biology.
[228] D. Betteridge,et al. Decreased prostacyclin sensitivity of platelets in patients with Behçet's syndrome , 1988, European journal of clinical investigation.
[229] A. Markel,et al. PLATELET FUNCTION IN BEHÇET'S DISEASE , 1984, The Journal of dermatology.
[230] K. Johnson. An Update. , 1984, Journal of food protection.
[231] J. Oppenheimer,et al. A Reassessment , 1979 .
[232] R. Walsa. [The syndrome]. , 1975, Orvosi hetilap.